Mark Hahn
2021 - Verona Pharma plc
In 2021, Mark Hahn earned a total compensation of $738.3K as Chief Financial Officer at Verona Pharma plc, a 96% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $218,875 |
|---|---|
| Salary | $402,500 |
| Stock Awards | $99,210 |
| Other | $17,704 |
| Total | $738,289 |
Hahn received $402.5K in salary, accounting for 55% of the total pay in 2021.
Hahn also received $218.9K in non-equity incentive plan, $99.2K in stock awards and $17.7K in other compensation.
Rankings
In 2021, Mark Hahn's compensation ranked 9,722nd out of 12,405 executives tracked by ExecPay. In other words, Hahn earned more than 21.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,722 out of 12,405 | 22nd |
Division Manufacturing | 4,304 out of 5,494 | 22nd |
Major group Chemicals And Allied Products | 1,908 out of 2,369 | 20th |
Industry group Drugs | 1,693 out of 2,090 | 19th |
Industry Pharmaceutical Preparations | 1,257 out of 1,537 | 18th |
Source: SEC filing on March 22, 2022.
Hahn's colleagues
We found three more compensation records of executives who worked with Mark Hahn at Verona Pharma plc in 2021.